Market Overview

Atlas Venture Announces $250 Million Opportunity Fund


New fund will invest growth capital in Atlas-backed biotech companies

, a leading venture capital firm investing in breakthrough
biotech innovation, today announced the closing of its first Opportunity
Fund, raising $250 million in an oversubscribed fundraise. With Atlas
Venture Opportunity Fund I (AVOF I), the firm will invest in existing
Atlas portfolio companies as they progress.

"We are delighted and humbled by the support of our limited partners in
this natural extension of our venture creation investment model," said
Atlas partner Kevin Bitterman. "Atlas' longstanding and new limited
partners alike have demonstrated their conviction in the ability of our
portfolio companies to advance innovative therapeutics for patients in

Together with experienced entrepreneurs-in-residence, Atlas Venture
creates new biotech startups to discover and develop novel medicines.
The firm takes a hands-on approach to building companies and incubates
many of them in the firm's Kendall Square space. Atlas' early stage
funds, which focus on new company formation, are complemented by AVOF I
which will invest in high-potential portfolio companies as they grow
through Series B financings and beyond.

Atlas Venture has been building biotechnology companies for more than
two decades. The same team of five investing partners will invest AVOF
I: Kevin Bitterman, Bruce Booth, Jean-François Formela, David Grayzel,
and Jason Rhodes.

About Atlas Venture

Atlas Venture is a leading biotech venture capital firm. With the goal
of doing well by doing good, we have been building breakthrough biotech
startups since 1993. We work side by side with exceptional scientists
and entrepreneurs to translate high impact science into medicines for
patients. Our seed-led venture creation strategy rigorously selects and
focuses investment on the most compelling opportunities to build
scalable businesses and realize value. For more information, please

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at